Quantitative assessment of the association between glutathione S-transferase P1 Ile105Val polymorphism and bladder cancer risk

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1651-1657

  Wang, Zhenlong ^a   Xue, Li ^a   Chong, Tie ^a   Li, Hecheng ^a   Chen, Haiwen ^a   Wang, Ziming ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Bladder cancer; GSTP1 Ile105Val; Meta analysis; Polymorphism

Indexed keywords

GLUTATHIONE TRANSFERASE P1; ISOLEUCINE; VALINE;

ARTICLE; BLADDER CANCER; CANCER RISK; CONTROLLED STUDY; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; GLUTATHIONE TRANSFERASE P1 GENE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

EID: 84878702534     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0698-y     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239-49.
3. Sanchez-Carbayo M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol. 2012;33:347-61.
4. Pandith AA, Siddiqi MA. Burden of cancers in the valley of Kashmir: 5 year epidemiological study reveals a different scenario. Tumour Biol. 2012;33:1629-37.
5. Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev. 2009;28:269-80.
6. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51-88.
7. Moyer AM, Salavaggione OE, Wu TY, Moon I, Eckloff BW, Hildebrandt MA, et al. Glutathione S-transferase P1: gene sequence variation and functional genomic studies. Cancer Res. 2008;68:4791-801.
8. Ritchie KJ, Walsh S, Sansom OJ, Henderson CJ, Wolf CR. Markedly enhanced colon tumorigenesis in Apc(Min) mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A. 2009;106:20859-64.
9. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics. 1998;8:27-31.
10. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998;19:275-80.
11. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 1997;18:641-4.
12. Katoh T, Kaneko S, Takasawa S, Nagata N, Inatomi H, Ikemura K, et al. Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics. 1999;9:165-9.
13. Steinhoff C, Franke KH, Golka K, Thier R, Romer HC, Rotzel C, et al. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol. 2000;74:521-6.
14. Toruner GA, Akyerli C, Ucar A, Aki T, Atsu N, Ozen H, et al. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Arch Toxicol. 2001;75:459-64.
15. Ma QW, Lin GF, Chen JG, Shen JH. Polymorphism of glutathione S-transferase T1, M1 and P1 genes in a Shanghai population: patients with occupational or non-occupational bladder cancer. Biomed Environ Sci. 2002;15:253-60.
16. Ma Q, Lin G, Qin Y, Lu D, Golka K, Geller F, et al. GSTp1 A1578G (Ile105val) polymorphism in benzidine-exposed workers: an association with cytological grading of exfoliated urothelial cells. Pharmacogenetics. 2003;13:409-15.
17. Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004;110:598-604.
18. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263-71.
19. Cao W, Cai L, Rao JY, Pantuck A, Lu ML, Dalbagni G, et al. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer. 2005;104:2400-8.
20. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, gstm1 null genotype, and risk of bladder cancer: results from the spanish bladder cancer study and meta-analyses. Lancet. 2005;366:649-59.
21. Mittal RD, Srivastava DS, A M, B M. Genetic polymorphism of drug metabolizing enzymes (cyp2e1, gstp1) and susceptibility to bladder cancer in north india. Asian Pac J Cancer Prev 2005;6:6-9.
22. Saad AA, O'Connor PJ, Mostafa MH, Metwalli NE, Cooper DP, Povey AC, et al. Glutathione S-transferase M1, T1 and P1 polymorphisms and bladder cancer risk in Egyptians. Int J Biol Markers. 2005;20:69-72.
23. Srivastava DS, Mishra DK, Mandhani A, Mittal B, Kumar A, Mittal RD. Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer. Eur Urol. 2005;48:339-44.
24. Hsu LI, Chiu AW, Huan SK, Chen CL, Wang YH, Hsieh FI, et al. SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. Toxicol Appl Pharmacol. 2008;228:144-55.
25. Kopps S, Angeli-Greaves M, Blaszkewicz M, Prager HM, Roemer HC, Lohlein D, et al. Glutathione S-transferase P1 Ile105Val polymorphism in occupationally exposed bladder cancer cases. J Toxicol Environ Health A. 2008;71:898-901.
26. Yuan JM, Chan KK, Coetzee GA, Castelao JE, Watson MA, Bell DA, et al. Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis. 2008;29:1386-93.
27. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol. 2009;41:259-66.
28. Fontana L, Delort L, Joumard L, Rabiau N, Bosviel R, Satih S, et al. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res. 2009;29:1631-5.
29. Grando JP, Kuasne H, Losi-Guembarovski R, Sant'ana Rodrigues I, Matsuda HM, Fuganti PE, et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med. 2009;9:21-8.
30. Jiang X, Castelao JE, Yuan JM, Groshen S, Stern MC, Conti DV, et al. Hypertension, diuretics and antihypertensives in relation to bladder cancer. Carcinogenesis. 2010;31:1964-71.
31. Hsu LI, Chen WP, Yang TY, Chen YH, Lo WC, Wang YH, et al. Genetic polymorphisms in glutathione S-transferase (GST) superfamily and risk of arsenic-induced urothelial carcinoma in residents of southwestern Taiwan. J Biomed Sci. 2011;18:51.
32. Reszka E, Jablonowski Z, Wieczorek E, Gromadzinska J, Sosnowski M, Wasowicz W. GSTP1 mRNA expression in human circulating blood leukocytes is associated with GSTP1 genetic polymorphism. Clin Biochem. 2011;44:1153-5.
33. Safarinejad MR, Safarinejad S, Shafiei N (2011) Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility. Urol Oncol. doi: 10.1016/j.urolonc.2011.11.027.
34. Zhang R, Xu G, Chen W, Zhang W. Genetic polymorphisms of glutathione S-transferase P1 and bladder cancer susceptibility in a Chinese population. Genet Test Mol Biomarkers. 2011;15:85-8.
35. Lesseur C, Gilbert-Diamond D, Andrew AS, Ekstrom RM, Li Z, Kelsey KT, et al. A case-control study of polymorphisms in xenobiotic and arsenic metabolism genes and arsenic-related bladder cancer in New Hampshire. Toxicol Lett. 2012;210:100-6.
36. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
39. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-29.
40. Thompson SG, Higgins J. How should meta-regression analyses be undertaken and interpreted? Statistics in medicine. 2002;21:1559-73.
41. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15-7.
42. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.
43. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
44. Chang J, Dinney CP, Huang M, Wu X, Gu J. Genetic variants in telomere-maintenance genes and bladder cancer risk. PLoS One. 2012;7:e30665.
45. Gong M, Dong W, An R. Glutathione S-transferase T1 polymorphism contributes to bladder cancer risk: a meta-analysis involving 50 studies. DNA Cell Biol. 2012;31:1187-97.
46. Zhang Y, Wang X, Zhang W, Gong S. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis. Tumour Biol. 2012. doi: 10.1007/s13277-012-0633-7.
47. Cahill LE, Fontaine-Bisson B, El-Sohemy A. Functional genetic variants of glutathione S-transferase protect against serum ascorbic acid deficiency. Am J Clin Nutr. 2009;90:1411-7.